Salles G, Goswami B, Bagnardi V, et al. - In L-MIND, an ongoing, open-label, single-arm, phase 2 study, tafasitamab + LEN was evaluated in patients (pts) with R/R DLBCL who are ineligible for autologous stem cell transplant. Given that not all OS and PFS events may occur even during a long follow-up, there may be underestimation of survival benefit for tafasitamab + LEN in traditional survival analyses. Researchers sought to determine the proportion of long-term survivors (LTS) and survival advantage linked with tafasitamab + LEN treatment by employing mixture cure models. Kaplan–Meier (KM) plots of PFS and OS for 80/81 enrolled pts plateaued after 30 months in the L-MIND study; the majority of events (PFS: 45/46 [97.8%]; OS: 36/41 [87.8%]) were reported up to that time point. These PFS and OS KM curves for the L-MIND study suggest the presence of an LTS subgroup. The survival plateau of LTS may be missed in standard parametric models, resulting in a poor estimate of OS benefit in such pts. The mixture cure model indicates a high LTS proportion of 42.5% in correlation with the treatment of R/R DLBCL pts with tafasitamab + LEN.